Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy
Obstetrics & Gynecology Science
; : 285-289, 2019.
Article
en En
| WPRIM
| ID: wpr-760645
Biblioteca responsable:
WPRO
ABSTRACT
The long-term survival of heavily pretreated patients with primary peritoneal cancer (PPC) is uncommon. Here, we report on a patient with PPC refractory to multiple lines of intravenous chemotherapy, namely, a combined regimen of paclitaxel and carboplatin, and single regimens of topotecan, docetaxel, cisplatin, and gemcitabine. However, after intraperitoneal (IP) chemotherapy with paclitaxel-cisplatin, the patient's condition improved, and she has been progression-free for more than 4 years. Interestingly, before the IP chemotherapy, the recurrences were limited to the peritoneal cavity. These results suggest that IP recurrence might be a predictor of a good response to IP chemotherapy.
Palabras clave
Texto completo:
1
Banco de datos:
WPRIM
Asunto principal:
Neoplasias Ováricas
/
Cavidad Peritoneal
/
Neoplasias Peritoneales
/
Recurrencia
/
Carboplatino
/
Cisplatino
/
Paclitaxel
/
Topotecan
/
Quimioterapia
/
Infusiones Parenterales
Límite:
Humans
Idioma:
En
Revista:
Obstetrics & Gynecology Science
Año:
2019
Tipo del documento:
Article